Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 10 search results for " Erlotinib" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
Tips for Coping With Chemotherapy Mouth Sores
... The chemotherapy and targeted medications for lung cancer that can potentially cause mouth sores include:Capecitabine (Xeloda)Cisplatin (Platinol)Cytarabine (DepoCyt)Doxorubicin (sold as Doxil and Adriamycin)Etoposide (VP-16)FluorouracilMethotrexate EGFR inhibitors, including erlotinib, afatinib, osimertinib, and dacomitinibChemotherapy’s effect on ...
Tips for Coping With Chemotherapy Mouth Sores
... The chemotherapy and targeted medications for lung cancer that can potentially cause mouth sores include:Capecitabine (Xeloda)Cisplatin (Platinol)Cytarabine (DepoCyt)Doxorubicin (sold as Doxil and Adriamycin)Etoposide (VP-16)FluorouracilMethotrexate EGFR inhibitors, including erlotinib, afatinib, osimertinib, and dacomitinibChemotherapy’s effect on ...
5 Treatment Types for Advanced NSCLC
... Systematic Review — Annals of Translational Medicine Targeted Therapy — National Cancer Institute Tyrosine Kinase Inhibitor — National Cancer Institute Lung Cancer Genomic Testing (EGFR, KRAS, ALK) — Memorial Sloan Kettering Cancer Center Meta-Analysis of Targeted Therapies in EGFR-Mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib ...
5 Treatment Types for Advanced NSCLC
... Systematic Review — Annals of Translational Medicine Targeted Therapy — National Cancer Institute Tyrosine Kinase Inhibitor — National Cancer Institute Lung Cancer Genomic Testing (EGFR, KRAS, ALK) — Memorial Sloan Kettering Cancer Center Meta-Analysis of Targeted Therapies in EGFR-Mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib ...
Clinical Trials for NSCLC: What To Ask Your Doctor
... References Recent Advances in the Management of Lung Cancer — Clinical Medicine (London) FDA Drug Approval Summary: Erlotinib (Tarceva) Tablets — The Oncologist FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond — The Oncologist Recent Advances in Lung Cancer Treatment Resulting ...
Clinical Trials for NSCLC: What To Ask Your Doctor
... References Recent Advances in the Management of Lung Cancer — Clinical Medicine (London) FDA Drug Approval Summary: Erlotinib (Tarceva) Tablets — The Oncologist FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond — The Oncologist Recent Advances in Lung Cancer Treatment Resulting ...
EGFR-Positive Lung Cancer: 5 Facts To Know
... These are known as first-generation TKIs and include the drugs erlotinib (Tarceva) and gefitinib (Iressa). First-generation TKIs are used to treat people with EGFR mutations in exon 19 or 21. ...
EGFR-Positive Lung Cancer: 5 Facts To Know
... These are known as first-generation TKIs and include the drugs erlotinib (Tarceva) and gefitinib (Iressa). First-generation TKIs are used to treat people with EGFR mutations in exon 19 or 21. ...
NSCLC Targeted Therapy: 8 Facts
... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
NSCLC Targeted Therapy: 8 Facts
... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
6 Lung Cancer Mutations and Treatments That Target Them
... Food and Drug Administration (FDA) for lung cancers containing EGFR mutations: Erlotinib (Tarceva) Gefitinib (Iressa) Afatinib (Gilotrif) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) You can learn more about these medications and other treatments for lung cancer here.2. ...
6 Lung Cancer Mutations and Treatments That Target Them
... Food and Drug Administration (FDA) for lung cancers containing EGFR mutations: Erlotinib (Tarceva) Gefitinib (Iressa) Afatinib (Gilotrif) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) You can learn more about these medications and other treatments for lung cancer here.2. ...
Posttreatment Lung Cancer Rash: Photos and Tips To Soothe
... Mechanism and Treatment — Cancer Management and Research Radiation Dermatitis: An Overview — International Journal of Dermatology Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy — Dermatology and Therapy Chemotherapy and Skin Reactions — Journal of Experimental & Clinical Cancer Research Acneiform Rash During Lung Cancer Therapy With Erlotinib ...
Posttreatment Lung Cancer Rash: Photos and Tips To Soothe
... Mechanism and Treatment — Cancer Management and Research Radiation Dermatitis: An Overview — International Journal of Dermatology Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy — Dermatology and Therapy Chemotherapy and Skin Reactions — Journal of Experimental & Clinical Cancer Research Acneiform Rash During Lung Cancer Therapy With Erlotinib ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... mutations.The many types of targeted therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... mutations.The many types of targeted therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib ...
How Does Targeted Therapy for Lung Cancer Work?
... TKIs for EGFR mutations include: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) is often used when a person’s cancer becomes resistant to earlier-generation EGFR inhibitors. More recently, osimertinib also was approved as a first-line treatment for some people with EGFR-mutated NSCLC. ...
How Does Targeted Therapy for Lung Cancer Work?
... TKIs for EGFR mutations include: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) is often used when a person’s cancer becomes resistant to earlier-generation EGFR inhibitors. More recently, osimertinib also was approved as a first-line treatment for some people with EGFR-mutated NSCLC. ...